Showing 1 - 10 of 6,489
Persistent link: https://www.econbiz.de/10002934120
Persistent link: https://www.econbiz.de/10003139150
Persistent link: https://www.econbiz.de/10001645083
assessment in Germany since its introduction in 2011 up to September 2016. Methods: It was differentiated between additive (new …
Persistent link: https://www.econbiz.de/10012291135
Persistent link: https://www.econbiz.de/10003423495
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...
Persistent link: https://www.econbiz.de/10013286496
Persistent link: https://www.econbiz.de/10000868176
Persistent link: https://www.econbiz.de/10000825461
To control Medicaid's increasing expenditure on reimbursement of outpatient prescription drugs, the Omnibus Budget Reconciliation Act of 1990 included a rebate program that featured a most favored customer (MFC) clause. This clause guarantees that Medicaid gets a fixed rebate on each unit of...
Persistent link: https://www.econbiz.de/10003898336
Persistent link: https://www.econbiz.de/10003456103